Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2011

01-10-2011 | Gastrointestinal Oncology

COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Authors: Yasunori Akutsu, MD, PhD, Naoyuki Hanari, MD, PhD, Gulbostan Yusup, MD, Aki Komatsu-Akimoto, MS, Norimasa Ikeda, MD, Mikito Mori, MD, PhD, Yasuo Yoneyama, MD, PhD, Satoshi Endo, MD, Yukimasa Miyazawa, MD, PhD, Hisahiro Matsubara, MD, PhD

Published in: Annals of Surgical Oncology | Issue 10/2011

Login to get access

Abstract

Purpose

The overexpression of cyclooxygenase (COX)2 is correlated with carcinogenesis, tumor progression, and prognosis, and increased COX2 expression is correlated with radiation resistance. However, no correlation between the COX2 expression and resistance to chemoradiotherapy for esophageal squamous cell carcinoma has been characterized. The purpose of the present study was to evaluate whether COX2 expression is an indicator of resistance to chemoradiotherapy in esophageal squamous cell carcinoma and the feasibility of COX2 as a biomarker for CRT.

Methods

Fifty-eight patients who were diagnosed with esophageal squamous cell carcinoma from biopsy samples were enrolled in the present series. All patients underwent concurrent chemoradiotherapy in a neoadjuvant setting, followed by radical esophagectomy. COX2 expression was evaluated by immunohistochemical staining and statistically compared with the histopathologic findings in surgically resected specimens.

Results

The rate of responders was 87% for weak expression of COX2, 62% for moderate expression, and 30% for strong expression, and there was a close correlation between COX2 expression and the response rate (Kendall’s τb = 0.396, P = 0.001). In the univariate analysis, negative or weak expression of COX2 was found to correlate significantly with CRT response (odds ratio, 6.296; 95% confidence interval (CI), 1.58–25.096; P = 0.010). In the multivariate analysis, weak expression of COX2 (30% or less) was found to be an independent prognostic factor (odds ratio, 6.534; 95% CI, 1.535–27.803; P = 0.011).

Conclusions

The COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma, and it also is a feasible biomarker for evaluating the CRT response.
Literature
1.
2.
Akutsu Y, Matsubara H, Shuto K, et al. Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg. 2009;33(5):1002–9.PubMedCrossRef
3.
Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145–82.PubMedCrossRef
4.
Dempke W, Rie C, Grothey A, et al. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001;127(7):411–7.PubMedCrossRef
5.
Shamma A, Yamamoto H, Doki Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res. 2000;6(4):1229–38.PubMed
6.
Lucci A, Krishnamurthy S, Singh B, et al. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat. 2009;117(1):61–8.PubMedCrossRef
7.
Hashimoto N, Inayama M, Fujishima M, et al. Clinicopathologic significance of expression of cyclooxygenase-2 in human esophageal squamous cell carcinoma. Hepatogastroenterology. 2007;54(75):758–60.PubMed
8.
van Nes JG, de Kruijf EM, Faratian D, et al. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat. 2011;125(3):671–85.PubMedCrossRef
9.
Pai R, Soreghan B, Szabo IL, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8(3):289–93.PubMedCrossRef
10.
Yasumaru M, Tsuji S, Tsujii M, et al. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res. 2003;63(20):6726–34.PubMed
11.
Anai S, Tanaka M, Shiverick KT, et al. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells. J Urol. 2007;177(5):1913–7.PubMedCrossRef
12.
Takubo K, Makuuchi H, Hujita H, et al. Japanese classification of esophageal cancer, 10th edn: part I. Esophagus. 2009;6(1):1–25.CrossRef
13.
Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1–24.PubMedCrossRef
14.
Nikitakis NG, Hebert C, Lopes MA, et al. PPARgamma-mediated antineoplastic effect of NSAID sulindac on human oral squamous carcinoma cells. Int J Cancer. 2002;98(6):817–23.PubMedCrossRef
15.
Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 1997;94(7):3336–40.PubMedCrossRef
16.
Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996;56(11):2556–60.PubMed
17.
Wild PJ, Kunz-Schughart LA, Stoehr R, et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol. 2005;27(2):385–91.PubMed
18.
Witton CJ, Hawe SJ, Cooke TG, et al. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004;45(1):47–54.PubMedCrossRef
19.
Edwards J, Mukherjee R, Munro AF, et al. HER2 and COX2 expression in human prostate cancer. Eur J Cancer. 2004;40(1):50–5.PubMedCrossRef
20.
Fux R, Schwab M, Thon KP, et al. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res. 2005;11(13):4754–60.PubMedCrossRef
21.
Wijnhoven BP, van Lanschot JJ, Tilanus HW, et al. Neoadjuvant chemoradiotherapy for esophageal cancer: a review of meta-analyses. World J Surg. 2009;33(12):2606–14.PubMedCrossRef
22.
Li Y, Niu Y, Wu H, et al. PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo. Cancer Sci. 2009;100(12):2451–8.PubMedCrossRef
23.
Tendo M, Yashiro M, Nakazawa K, et al. Inhibitory effect of a selective cyclooxygenase inhibitor on the invasion-stimulating activity of orthotopic fibroblasts for scirrhous gastric cancer cells. Cancer Sci. 2005;96(7):451–5.PubMedCrossRef
24.
Kaneko M, Kaneko S, Suzuki K. Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts. Cancer Sci. 2009;100(11):2193–201.PubMedCrossRef
25.
Zhao S, Cai J, Bian H, et al. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. Cancer Invest. 2009;27(6):636–40.PubMedCrossRef
26.
Palayoor ST, Bump EA, Calderwood SK, et al. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res. 1998;4(3):763–71.PubMed
27.
Irie T, Tsujii M, Tsuji S, et al. Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma. Int J Cancer. 2007;121(4):878–83.PubMedCrossRef
28.
Kang KB, Wang TT, Woon CT, et al. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys. 2007;67(3):888–96.PubMedCrossRef
29.
Kuipers GK, Slotman BJ, Wedekind LE, et al. Radiosensitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. Int J Radiat Biol. 2007;83(10):677–85.PubMedCrossRef
30.
Shin YK, Park JS, Kim HS, et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res. 2005;65(20):9501–9.PubMedCrossRef
31.
Jun HJ, Kim YM, Park SY, et al. Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib. Int J Radiat Oncol Biol Phys. 2009;75(1):225–34.PubMedCrossRef
32.
Raju U, Ariga H, Dittmann K, et al. Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol Phys. 2005;63(2):520–8.PubMedCrossRef
33.
Kim BM, Won J, Maeng KA, et al. Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3. Int J Oncol. 2009;34(5):1467–73.PubMed
34.
Dawson SJ, Michael M, Biagi J, et al. A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs. 2007;25(2):123–9.PubMedCrossRef
Metadata
Title
COX2 Expression Predicts Resistance to Chemoradiotherapy in Esophageal Squamous Cell Carcinoma
Authors
Yasunori Akutsu, MD, PhD
Naoyuki Hanari, MD, PhD
Gulbostan Yusup, MD
Aki Komatsu-Akimoto, MS
Norimasa Ikeda, MD
Mikito Mori, MD, PhD
Yasuo Yoneyama, MD, PhD
Satoshi Endo, MD
Yukimasa Miyazawa, MD, PhD
Hisahiro Matsubara, MD, PhD
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1645-z

Other articles of this Issue 10/2011

Annals of Surgical Oncology 10/2011 Go to the issue

Gastrointestinal Oncology

Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays

Head and Neck Oncology

Low-Dose Preoperative Chemoradiation Therapy Compared with Surgery Alone with or Without Postoperative Radiotherapy in Patients with Head and Neck Carcinoma

Urologic Oncology

Radical Prostatectomy Versus External-Beam Radiotherapy for Localized Prostate Cancer: Long-Term Effect on Biochemical Control—In Search of the Optimal Treatment

Colorectal Cancer

Risk Factors for Anastomotic Leakage after Rectal Cancer Resection and Reconstruction with Colorectostomy. A Retrospective Study with Bootstrap Analysis

Thoracic Oncology

Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma

Endocrine Tumors

Diffuse Microcalcifications Only of the Thyroid Gland Seen on Ultrasound: Clinical Implication and Diagnostic Approach